Archiv
Archiv anzeigen:
bis


Combination Therapy for Metastatic Prostate Cancer

Robert Dreicer, MD, MS, FACP, FASCO reviewing James ND et al. N Engl J Med 2017 Jun 3, Fizazi K et al. N Engl J Med 2017 Jun 4

Adding abiraterone and prednisone to androgen-deprivation therapy significantly improved survival.


Predicting Mortality in Thrombotic Thrombocytopenic Purpura

David Green, MD, PhD reviewing Alwan F et al. Blood 2017 Jun 2

Mortality was highest in patients with ADAMTS13 antibody levels in the highest quartile and ADAMTS13 antigen levels in the lowest quartile.


Value of Clinical Breast Examination When Screening Mammography Is Not Readily Available

Andrew M. Kaunitz, MD reviewing Romanoff A et al. JAMA Oncol 2017 May 25

Small Peruvian study suggests prior CBE may lead women with self-detected breast cancer to present earlier for care.


Ixazomib for Relapsed or Refractory Light-Chain Amyloidosis

David Green, MD, PhD reviewing Sanchorawala V et al. Blood 2017 May 26

The hematologic response rate was 52% among patients who received the maximum tolerated dose.


TDM-1 for HER2-Positive Esophagogastric Cancer

David H. Ilson, MD, PhD reviewing Thuss-Patience PC et al. Lancet Oncol 2017 May 1

Survival with drug-antibody conjugate trastuzumab emtansine was not superior to that with taxane therapy.


Stem-Cell Transplantation Ineffective for Double-Hit Lymphoma

Michael E. Williams, MD, ScM reviewing Landsburg DJ et al. J Clin Oncol 2017 May 5

Consolidative autologous SCT did not improve survival for patients in first remission after induction chemoimmunotherapy.


Prostate Cancer Molecular Subtypes: How Predictive or Prognostic?

Robert Dreicer, MD, MS, FACP, FASCO reviewing Zhao SG et al. JAMA Oncol 2017 May 11, Abida W and Scher HI. JAMA Oncol 2017 May 11

Patients with luminal B tumors respond better to postoperative androgen-deprivation therapy than do those with non–luminal B tumors.


Bendamustine and Rituximab for Chronic Cold Agglutinin Disease

David Green, MD, PhD reviewing Berentsen S et al. Blood 2017 May 22

Complete response was achieved by 40% of patients.


Chromosome Instability May Be Prognostic in Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Jamal-Hanjani M et al. N Engl J Med 2017 Apr 26

Intratumor heterogeneity is associated with an increased risk for disease recurrence or death.


Nivolumab for Esophageal Squamous-Cell Cancer

David H. Ilson, MD, PhD reviewing Kudo T et al. Lancet Oncol 2017 May

A phase II trial demonstrates activity in patients with chemotherapy-refractory disease.


Archiv
Seite von 56
Editorial Member Board Empfehlungen

Prof. Dr. med. Florian Otto

Tumor- und Brustzentrum ZeTuP, St. Gallen

E-Mail: E-Mail anzeigen

Liebe Kolleginnen und Kollegen!

Immuntherapie ist in aller Munde. Checkpoint-Inhibitoren werden bei praktisch allen onkologischen Erkrankungen erprobt und erweisen sich häufig als wirksam – zumindest für eine gewisse Zeit. Aber wie entwickelt sich eine Resistenz? Dieser Frage sind Zaretsky und Kollegen im Kontext von vier Melanompatienten unter Pembrolizumab-Therapie nachgegangen und haben Defekte im Interferon-Signalweg sowie der Antigenpräsentation in den Tumorzellen gefunden.

Kommentar weiterlesen

Management of Localized Prostate Cancer: Data at Last

Robert Dreicer, MD, MS, FACP, FASCO reviewing Hamdy FC et al. N Engl J Med 2016 Sep 14, D'Amico AV. N Engl J Med 2016 Sep 14

Mortality was similar with active monitoring, prostatectomy, or radiotherapy during 10 years of follow-up.


Hereditary Thrombophilia and Risk for Pregnancy-Associated Venous Thromboembolism

David Green, MD, PhD reviewing Gerhardt A et al. Blood 2016 Sep 9

Pregnant women with inherited thrombophilia have increased risk for VTE, independent of a family history of VTE.


Little Benefit to Extensive Breast Cancer Monitoring

William J. Gradishar, MD reviewing Accordino MK et al. J Clin Oncol 2016 Aug 20, Smith KL and Smith TJ. J Clin Oncol 2016 Aug 20

The use of >12 serum tumor marker tests and/or 4 radiographic imaging tests per year provided no survival advantage.


FOLFOX Equals or Betters Epirubicin, Cisplatin, and Fluorouracil in Esophagogastric Cancer

David H. Ilson, MD, PhD reviewing Enzinger PC et al. J Clin Oncol 2016 Aug 10

Adding epirubicin to fluorouracil/platinum-based chemotherapy resulted in greater toxicity and no clear improvement in response.


Reversing Anticoagulant-Associated Bleeding with Andexanet

David Green, MD, PhD reviewing Connolly SJ et al. N Engl J Med 2016 Aug 30

Andexanet reduced anti–factor Xa activity and restored effective hemostasis in patients with major bleeding.


Another Tool to Help Breast Cancer Patients Avoid Chemotherapy

William J. Gradishar, MD reviewing Cardoso F et al. N Engl J Med 2016 Aug 25, Hudis CA and Dickler M. N Engl J Med 2016 Aug 25

A 70-gene signature identified patients with high clinical risk and low molecular risk who achieved a 5-year survival rate of 94.7% without chemotherapy.


Daratumumab for Advanced Light Chain Amyloidosis

David Green, MD, PhD reviewing Sher T et al. Blood 2016 Aug 19

Declines in light chain levels were achieved in heavily pretreated patients.


HER2 a Potential Target in Colorectal Cancer

David H. Ilson, MD, PhD reviewing Sartore-Bianchi A et al. Lancet Oncol 2016 Jun

The HER2-targeted combination regimen of trastuzumab and lapatinib may have activity in HER2-positive, chemotherapy-refractory disease.


Resistance to Anti–PD-1 Therapy in Melanoma Patients

Jeffrey A. Sosman, MD reviewing Zaretsky JM et al. N Engl J Med 2016 Jul 13

Mutations preventing interferon-receptor signaling and antigen presentation are linked to acquired resistance.


Adjuvant S-1 for Resected Pancreatic Cancer

David H. Ilson, MD, PhD reviewing Uesaka K et al. Lancet 2016 Jun 2, Ko AH et al. Lancet 2016 Jun 2

Overall survival was significantly better with S-1 versus gemcitabine.